Regranex and Dermatitis - a phase IV clinical study of FDA data

Summary:

Dermatitis is reported as a side effect among people who take Regranex (becaplermin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Omeprazole, and have Metastases to bone.

The phase IV clinical study analyzes which people have Dermatitis when taking Regranex. It is created by eHealthMe based on reports of 2,565 people who have side effects when taking Regranex from the FDA, and is updated regularly.

What is Regranex?

Regranex has active ingredients of becaplermin. eHealthMe is studying from 2,565 Regranex users. Check the latest studies of Regranex.

What is Dermatitis?

Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it) is found to be associated with 1,547 drugs and 1,231 conditions by eHealthMe. Check the latest studies of Dermatitis.

On Jul, 19, 2026

2,565 people reported to have side effects when taking Regranex.
Among them, 18 people (0.7%) have Dermatitis.

Among these 18 people:

How long have people been on Regranex when they have Dermatitis? *

What is the gender of people who have Dermatitis when taking Regranex? *

female: 64.71 %
male: 35.29 %

What is the age of people who have Dermatitis when taking Regranex? *

What are other drugs people take besides Regranex? *

What are other side effects people have besides Dermatitis? *

Wound Infection: 6 people, 33.33%
Disability: 6 people, 33.33%
Dyshidrotic Eczema (skin condition in which blisters develop on the soles of your feet and/or the palms of hands): 6 people, 33.33%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 6 people, 33.33%
Facet Joint Syndrome (problem with movement of the facet joints of the spine): 6 people, 33.33%
Fungal Infection: 6 people, 33.33%
Gastric Ulcer (stomach ulcer): 6 people, 33.33%
Haemorrhagic Erosive Gastritis (bleeding from peptic ulcer disease): 6 people, 33.33%
Hair Loss: 6 people, 33.33%
Hepatic Mass: 6 people, 33.33%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 6 people, 33.33%
Diabetic Foot: 2 people, 11.11%
Weight Loss: 1 person, 5.56%
Oesophagitis (inflammation of oesophagus): 1 person, 5.56%
Gastritis (inflammation of stomach): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Regranex and have Dermatitis?

- Check whether Dermatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Regranex:

Regranex (2,565 reports)

Dermatitis treatments and more:

Dermatitis (30,577 reports)

Browse all side effects of Regranex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis:

Dermatitis (1,547 drugs)

Browse all the conditions that are associated with Dermatitis:

Dermatitis (1,231 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on becaplermin (the active ingredients of Regranex) and Regranex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.